A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.

导出 LinkOut

翻译打印收藏纠错

第一作者： N,Shuker

第一单位： Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.

作者： N,Shuker ^[1] ; R,Bouamar ^[2] ; R H N,van Schaik ^[2] ; M C,Clahsen-van Groningen ^[3] ; J,Damman ^[4] ; C C,Baan ^[5] ; J,van de Wetering ^[1] ; A T,Rowshani ^[1] ; W,Weimar ^[1] ; T,van Gelder ^[1] ; D A,Hesselink ^[1]

作者单位： Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. ^[1] Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, The Netherlands. ^[2] Department of Clinical Chemistry, Erasmus Medical Centre, Rotterdam, The Netherlands. ^[3] Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands. ^[4] Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands. ^[5]

关键词 calcineurin inhibitor: tacrolimus clinical research/practice genetics immunosuppressant immunosuppression/immune modulation kidney transplantation/nephrology pharmacokinetics/pharmacodynamics